BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
BioLineRx Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.98−0.03 (-1.49%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
80.5%
Operating margin
-871.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -95.9% | – | – | – | |
| Gross profit | -95.2% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 9.86 | 2.15 | 1.95 | |
| Interest coverage | -750.6× | -14.1× | -8.0× | |
| Inventory turnover | – | – | 0.1× | |
| Capex to revenue | – | – | 2.1% | |
| Diluted shares | 56M | 253M | 2.47B |
Where the cash went
Fiscal 2021 to 2025, five years combined
BioLineRx generated $124.37M from operations and spent $422.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$124.37M
Used
$422.00K
Capital expenditure$422.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$8.07M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$8.07M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.76 → 1.95
- No dilutionShare count did not rise1.20B → 2.47B
- Gross margin improvedGross margin up on the prior year67.99% → 80.51%
- More efficientAsset turnover rose0.45 → 0.03